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Background
TNF-a inhibitor (TNFi) therapy has revolutionized the
treatment of immune-mediated inflammatory diseases,
including rheumatoid arthritis (RA). IL-17-producing CD4
+ T-cells (Th17 cells) are considered important contribu-
tors to the pathogenesis of RA. Here we investigated the
effects of TNFi drugs on the function and plasticity of
human Th17 cells.
Methods
The frequency of cytokine-expressing cells was assessed
by flow cytometry. For functional studies, CD4+ T-cells
and autologous CD14+ monocytes were co-cultured with
anti-CD3 mAb in the absence or presence of different
TNFi drugs. Cytokine secretion assays were used to re-
sort cytokine-producing CD4+ T-cells.
Results
Ex vivo analysis of patients with RA on TNFi therapy
revealed an enrichment of Th17 cells in peripheral blood
compared to those on disease-modifying anti-rheumatic
drugs or healthy controls. However, we also found an
increase in IL-10-producing CD4+ T-cells. The enrich-
ment in IL-17+ and IL-10+ CD4+ T-cells, including IL-
17+IL-10+ co-expressing CD4+ T-cells, was recapitulated
in vitro by the addition of TNFi drugs (adalimumab,
infliximab, etanercept, and certolizumab) to human
monocyte/CD4+ T-cell co-cultures. IL-10 induction was
independent of FcgR binding, IL-10 and CD4+CD25+
Tregs. TNFi-induced Th17 cells were functionally dis-
tinct as shown by an ability to modulate CD14+ mono-
cytes in an IL-10-dependent manner. We report the
identification of a transcription factor that is strongly
associated with IL-10 expression in TNFi-induced IL-17+
CD4+ T-cells, and show that overexpression of this tran-
scription factor drives IL-10 expression in primary CD4+
T-cells.
Conclusions
TNFi drugs may exert their anti-inflammatory role, at
least in part, by promoting Th17 plasticity through the
induction of IL-10 expression in pathogenic Th17 cells.
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